5,948 Axon Enterprise, Inc $AXON Shares Purchased by Pinion Investment Advisors LLC

Pinion Investment Advisors LLC raised its position in Axon Enterprise, Inc (NASDAQ:AXON) by 991.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,548 shares of the biotechnology company’s stock after purchasing an additional 5,948 shares during the period. Pinion Investment Advisors LLC’s holdings in Axon Enterprise were worth $2,767,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. State Street Corp raised its position in shares of Axon Enterprise by 5,700.2% in the second quarter. State Street Corp now owns 213,561,844 shares of the biotechnology company’s stock valued at $119,724,905,000 after buying an additional 209,879,882 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in Axon Enterprise by 18,050.2% during the second quarter. Envestnet Asset Management Inc. now owns 13,200,075 shares of the biotechnology company’s stock worth $7,400,094,000 after acquiring an additional 13,127,348 shares during the last quarter. BlackRock Inc. boosted its position in Axon Enterprise by 4.3% during the second quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company’s stock worth $4,672,432,000 after acquiring an additional 345,365 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its position in Axon Enterprise by 391,214.9% during the third quarter. Robeco Institutional Asset Management B.V. now owns 6,988,884 shares of the biotechnology company’s stock worth $2,952,943,000 after acquiring an additional 6,987,098 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Axon Enterprise by 5,022.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,266,589 shares of the biotechnology company’s stock worth $1,802,719,000 after acquiring an additional 4,183,302 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on the company. JPMorgan Chase & Co. cut their price target on Axon Enterprise from $755.00 to $610.00 and set an “overweight” rating for the company in a report on Friday. Royal Bank Of Canada reduced their price target on Axon Enterprise from $735.00 to $615.00 and set an “outperform” rating on the stock in a research note on Friday. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a report on Tuesday, November 3rd. Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. Finally, Barclays lowered their price objective on Axon Enterprise from $688.00 to $507.00 and set an “overweight” rating for the company in a research report on Monday. Thirteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $612.18.

Insider Transactions at Axon Enterprise

In related news, President Joshua Isner sold 16,775 shares of Axon Enterprise stock in a transaction on Monday, August 31st. The stock was sold at an average price of $574.43, for a total value of $9,636,063.25. Following the transaction, the president owned 296,974 shares in the company, valued at approximately $170,590,774.82. This trade represents a 5.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $508.99, for a total value of $5,089,900.00. Following the completion of the transaction, the chief executive officer owned 3,118,012 shares in the company, valued at $1,587,036,927.88. The trade was a 0.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 37,397 shares of company stock valued at $21,234,034. Corporate insiders own 4.20% of the company’s stock.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $303.18 on Tuesday. Axon Enterprise, Inc has a one year low of $296.78 and a one year high of $665.07. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. The company has a 50 day moving average price of $435.58 and a 200 day moving average price of $473.66. The firm has a market capitalization of $24.63 billion, a price-to-earnings ratio of 97.17, a price-to-earnings-growth ratio of 8.06 and a beta of 1.48.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). The company had revenue of $908.55 million during the quarter, compared to analyst estimates of $934.33 million. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The firm’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.17 EPS. Sell-side analysts anticipate that Axon Enterprise, Inc will post 2.10 EPS for the current year.

Axon Enterprise Company Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.